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Objective: Until the present moment, the lack of efﬁcient therapeutic options available for
hyperhidrosis  treatment in obese patients has left this population without prospect of clini-
cal  or quality of life (QOL) improvements. Outcomes of oxybutynin treatment for overweight
and  obese patients with hyperhidrosis are unknown. This study aims to investigate the
results  related to clinical and QOL improvements in this speciﬁc population, submitted to a
12-week protocol treatment with oxybutynin.
Methods: 559 patients with palmar and axillary hyperhidrosis, routinely followed in this
service,  were divided into the groups, according to their body mass index (BMI) (< 25  kg/m2;
25 < BMI < 30 kg/m2, > 30 kg/m2). Improvements in QOL and in the level of hyperhidrosis
were  analyzed after 12  weeks of protocol treatment with oxybutynin. These parameters were
investigated using a scoring system based on a scientiﬁcally validated clinical questionnaire,
applied  before and after treatment.
Results: 67.8% of the overweight sample group and 63% of the obese patients presented
“partial”  or “great” improvement in the  level of hyperhidrosis. Over 65% of patients demon-
strated  improvement in QOL (“much better” or “slightly better”) for all three groups, with
no  statistical difference between them. The only adverse event associated with oxybutynin
was  dry mouth, observed in 63.0% of the  patients.
Conclusion: Overweight and obese patients with palmar or axillary hyperhidrosis present
signiﬁcant  improvement in QOL after treatment with oxybutynin, and the results are com-
parable  to those of normal weight individuals.
Eﬁcácia  da oxibutina  no  tratamento  de hiperidrose  em  pacientes
com  sobrepeso  e  obesos
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Objetivo: A  falta de alternativas terapêuticas para o tratamento de pacientes obesos com
hiperidrose  deixa essa populac¸ão  sem perspectiva de melhorar suas condic¸ões  clínicas e
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qualidade de  vida. Resultados do tratamento com oxibutinina especiﬁcamente em pacientes
com sobrepeso ou obesidade são desconhecidos até o presente momento. Este estudo tem
como objetivo investigar os resultados relacionados à  melhora clínica e qualidade de  vida
dessa populac¸ão,  após um protocolo de tratamento de  12 semanas com oxibutinina.
Métodos: 559 pacientes com hiperidrose palmar e axilar, foram divididos em três grupos, de
acordo com seu índice de massa corporal (IMC) (< 25 kg/m2; 25 < IMC < 30 kg/m2, > 30 kg/m2).
Dados sobre evoluc¸ão  na qualidade de vida e nível de hiperidrose foram avaliados com
base em um questionário validado cientiﬁcamente, aplicado antes e após o tratamento
com oxibutinina.
Resultados: 67.8% dos pacientes com sobrepeso e 63% dos obesos apresentaram melhora
clínica “grande” ou “parcial” no nível da hiperidrose. Mais de 65% dos pacientes relataram
melhora na qualidade de vida (“muito melhor” ou “um pouco melhor”) para os três gru-
pos, sem diferenc¸a  estatística entre eles. O  único efeito colateral observado foi boca seca,
presente em 63.0% da amostra.
Conclusão:  Pacientes com sobrepeso e obesidade portadores de hiperidrose palmar ou axilar
apresentaram melhora signiﬁcativa na  qualidade de  vida após o tratamento com oxibutin-
ina, sendo os resultados comparáveis aos de indivíduos com peso normal.
Introduction
Hyperhidrosis is  the production of excessive sweat beyond
what  is  required for the body’s thermoregulatory needs.1 Pal-
mar  (PH), plantar (PlH), and axillary hyperhidrosis (AH) are the
most  frequent presentations in both genders and across all age
groups. Hyperhidrosis affects approximately 3% of the general
population,  and actively interferes with patients’ quality of life
(QOL),  causing issues in social, professional, and emotional
spheres.2 The psychological stress caused by excessive sweat-
ing  is  the main drive for patients to seek medical assistance,
who  are usually willing to  undergo any possible treatment
option that will improve their QOL. Until the present moment,
the  lack of efﬁcient therapeutic options available for hyper-
hidrosis  treatment in obese patients has left this population
without prospect of improvements in QOL.
Overweight and obesity, deﬁned as body mass index (BMI)
greater  than 25  kg/m2 and 30 kg/m2, respectively, are the main
conditions  associated with more  severe sweating, possibly
as  a  result of reduced heat loss  due to thicker layers of fat
in  subcutaneous tissues. These patients have greater difﬁ-
culty  in maintaining normal body temperature levels, and
therefore produce excessive perspiration as a  compensatory
mechanism.3
Video-assisted thoracic sympathectomy (VATS) is currently
considered the optimal technique for treatment of primary
hyperhidrosis. It is a  safe, effective, and minimally inva-
sive  method;4–7 however, it presents limited applicability
in obese patients. Increased surgical risk, technical limita-
tions,  and more  severe levels of compensatory hyperhidrosis
explain why  surgical indications are  greatly restricted in these
individuals.8
Oxybutynin is  an anticholinergic medication widely used
in  urology for treatment of bladder urge incontinence. Sweat
glands  are  stimulated by acetylcholine; thus, the anticholin-
ergic  effect of oxybutynin is responsible for its effectiveness
against excessive sweating.9 It is a safe medication, with
few  absolute contraindications; the most important is  closed-
angle  glaucoma. Potential side effects include dry mouth,
constipation, headache, nausea, and urinary retention. Few
drug  interactions have been reported, and when present, they
involve  concomitant use of cytochrome P450 metabolism-
dependent medications.10,11
Recent studies have disclosed good results with the use of
oxybutynin for the treatment of hyperhidrosis.12–15 Nonethe-
less,  a  speciﬁc analysis of the effectiveness of this medication
in  obese patients had not been conducted. This study aimed
to  analyze QOL after treatment with oxybutynin in obese
patients with PH and AH, and to  compare the results with
those  of normal weight individuals.
Methods
This was a  retrospective study, based on medical chart review
of  559 patients treated with oxybutynin from January 2007 to
December  2011. The study was  approved by the ethics com-
mittee  of the institution.
The  patients involved were divided into three groups
according to their BMI. The ﬁrst group was  composed of 411
(73.5%)  normal weight patients (BMI < 25  kg/m2), the sec-
ond  consisted of 121 (21.6%) overweight patients (25< BMI
<  30 kg/m2), and the third, of 27 (4.9%) obese individuals (BMI
<  30 kg/m2).
Age, gender distribution, and location of hyperhidrosis
according to BMI  are shown in  Table 1. The lowest average
age  was  observed in  the  normal weight group. PH and female
gender  were predominant in all weight categories.
The same medical treatment protocol was  applied to all
patients.  During the  ﬁrst week, 2.5 mg  of oxybutynin were
administered once a day in the evening. From the eighth to
the  42nd day, the patients received 2.5 mg of the medication
twice  a day; from the  43rd day to the end of the 12th week, 5  mg
were  administered twice a  day. Experience has shown that a
staged administration reduces the impact of anticholinergic
side effects.
Patients were analyzed in three different moments dur-
ing  the study. The ﬁrst evaluation was  performed before the
start  of medication; the second, after six weeks of treatment;
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Table 1 – Age, site of hyperhidrosis, and gender distribution according to BMI.
BMI p
Variable < 25  25  <  BMI < 30  > 30
n (%) n (%) n (%)
Age
n 411 121 27
Range (min-max) 9-58 15-61 17-51 < 0.01a
Mean ±  SD  24.18 (±9.35) 30.0 (±  8.95)  30.8 (± 9.33)
Median  24  29  29
Site of  hyperhidrosis
Axilar 185 (45.0) 56  (46.3) 17  (62.9) 0.059b
Palmar 266 (55.0) 65  (53.7) 10  (37.1)
Gender
Female 310 (75.4) 64  (52.9) 16  (59.2) < 0.0001b
Male 101 (24.6) 57  (47.1) 11  (40.8)
BMI, body mass index.
a Student’s t-test;
b Chi-squared test.
and the  last evaluation, after the completion of 12 weeks of
treatment.  These evaluations were used to follow-up patients’
clinical  and QOL improvement. Clinical improvement was
classiﬁed  using a  scale ranging from 0 to  10, where 0  rep-
resented  no improvement, and 10  represented absence of
hyperhidrosis.  Clinical outcomes were  ranked according to the
following  categories: null (from 0 to 4), partial (5 to 7), or  great
(8  to  10).
QOL analysis was  based on a  validated clinical protocol
questionnaire, applied at each visit.16,17 The questionnaire
was  completed according to the patient’s perception of hyper-
hidrosis  improvement, without examiners’ interference. The
authors  believe that self-evaluation is a  reliable method for
patient  QOL analysis.
QOL  before treatment was  classiﬁed into ﬁve different sat-
isfaction  categories, calculated as  the added total score from
the  protocol (ranging from 20 to 100). According to the  sco-
ring  system, a greater score reﬂects a  more  signiﬁcant impact
and  represents poorer QOL. When the total score was equal
to  or greater than 84, QOL was  considered “very poor”. When
the  total score ranged from 68 to  83, QOL was  considered
“poor”. Scores that ranged from 52 to 67  were  considered
“good”. Scores from 36 to 51 indicated “very good” results, and
scores  from 20 to 35 were considered “excellent.
Similarly, improvement of QOL after treatment was also
classiﬁed  into ﬁve different levels. When the total was  equal
to  or greater than 84, the QOL was  considered to be “worse”.
When  the scores ranged from 68 to 83, QOL was  considered
to  be “slightly worse”. Scores from 46 to 58 were considered
“unaltered”. Scores from 33 to 45  indicated a  “slight improve-
ment”, and scores from 17 to 32 were considered “much
better”.
The  following parameters were studied in  both groups:
progress of PH and AH, evaluation of QOL before treatment,
and improvement in QOL after treatment.
Statystical  analysis
The chi-squared test was  performed to verify the associa-
tion between categorical variables in  contingency tables, and
Student’s  t-test was  used to compare age and study group. The
signiﬁcance  level considered for all statistical tests was  0.05.
Results
All patients enrolled in  the present study classiﬁed their QOL
before  treatment as  “poor” or “very poor”, as demonstrated in
Table 2. According to the present results, obese patients con-
sidered  themselves less affected by hyperhidrosis than normal
or  overweight individuals.
Approximately  69% of the normal BMI  group classiﬁed their
QOL  before treatment as “very poor”, whereas over 80% of
obese  individuals ranked their QOL as  simply “poor”. The
questionnaire was re-applied after the proposed period of
treatment;  over 65% of patients demonstrated improvement
in  QOL (“much better” or “slightly better”) for all three groups,
with  no statistical difference between them (Table 2).
Table  3 shows clinical improvement in  hyperhidrosis,
according to a  subjective evaluation based on the patient’s per-
ception  of his/her own symptoms. Over 60% of the  patients in
all groups presented partial or great improvement in  the level
of  sweating.
The only adverse event associated with oxybutynin was  dry
mouth,  observed in 255 cases (63.0%); however, none required
discontinuation of treatment, since in most cases the symp-
tom  was  classiﬁed as “light” and therefore tolerable.
Discussion
Obesity is a  condition with increasing incidence and preva-
lence  in many  parts of the world, and results from an
interaction of the environment, associated with genetic
predisposition and overall human behavior.15 Overweight
patients present increased risk of several diseases including
hypertension, osteoarthritis, diabetes, certain cancers, as  well
as psychological disorders.18,19 Concomitant hyperhidrosis
may  aggravate a  negative emotional state, resulting in further
deterioration of overall health conditions. This reinforces the
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Table 2  – Quality of life before and after treatment according to  BMI.
QOL before treatment Score BMI < 25 n (%)  25  < BMI < 30 n (%)  BMI > 30  n (%) pa
Very poor 84-100 283 (68.8) 41 (33.9) 5 (18.5) <  0.001
Poor  68-83 128 (31.2) 80 (66.1) 22  (81.5)
Good 52-67 - -  -
Very good 36-51 - -  -
Excellent 20-35 - -  -
Total 411 121 27
QOL after treatment Score BMI <  25  n (%) 25  < BMI <  30  n (%) BMI > 30  n (%) pb
Much better 17-32 140 (34.1) 37 (30.5) 5 (18.5)
Slightly  better 33-45 145 (35.3) 45 (37.2) 13  (48.1)
Unaltered 46-58 126 (30.6) 39 (32.3) 9 (33.4) 0.917
Slightly worse 68-83 - - -
Worse 84-100 - - -
Total  411 121 27
a Chi-squared test;
b Chi-squared test comparing “unaltered” with “much better” and “slightly better”.
signiﬁcant need for a  deﬁnitive treatment of hyperhidrosis in
this speciﬁc population.
BMI  is an estimation of body fat based on the  ratio of a
patient’s height to weight. Despite its limitations, it is one of
the  most commonly used anthropometric measures to assess
total  body adiposity, due to its simplicity, acceptable accuracy,
and  inexpensiveness.20 BMI  measurements are extensively
used in epidemiological studies, and are recommended as a
screening tool in the initial clinical assessment of obesity.12
The Centers for Disease Control and Prevention deﬁned
BMI  classiﬁcation as  follows: 1) underweight: BMI < 18.5 kg/m2;
2)  normal or acceptable weight: BMI  18.5–24.9 kg/m2; 3) over-
weight:  BMI  25–29.9 kg/m2; 4) obese: BMI  > 30 kg/m2.21 For the
purpose  of the present study, the relevant BMI cutoff is 25,
since  surgical procedures are limited in patients with BMI
above  this level.8
Unspeciﬁc questionnaires for QOL assessment do not allow
for  a precise analysis of patients with hyperhidrosis, since rel-
evant information for this disorder is not ordinarily addressed.
The  QOL questionnaire used in this study has been validated
and  used in several published documents.13,14 Its questions
focus on inﬂuence of hyperhidrosis in different daily life situ-
ations,  involving social, emotional, and professional activities.
The  higher predominance of hyperhidrosis observed in  the
female  gender is consistent with previous studies, and can be
explained by the greater concern that this condition imposes
to  women, leading them to seek medical assistance more
often.22
The group with BMI < 25 km/m2 showed a predominance
of “very poor” QOL classiﬁcation, higher than that observed in
the other two groups. Therefore, a  direct relationship between
level  of obesity and QOL before treatment was  not clearly
established in these study patients.
Improvements in hyperhidrosis after treatment were sim-
ilar  in all three groups, suggesting that overweight and obese
patients beneﬁt similarly to normal weight patients. This
may  be explained by the fact that QOL in  patients with
hyperhidrosis depends not only on the  intensity of sweat-
ing,  but also on how well the patient adapts to  his/her
situation.5 Normal weight individuals suffering with hyper-
hidrosis  may  perceive their condition as  greater in severity.
Excess  weight patients may  endure other more important
worries, and therefore may give less importance to hyper-
hidrosis.
Reports  on safety and adverse events regarding oxybutynin
are  based on the knowledge for treatment of urological blad-
der  conditions.23 Anticholinergic side effects are the most
frequent, and can occur in over 70% of patients using over
15  mg/day. The dose administered to the present patients was
rather  low (10 mg/day) in comparison to  what is commonly
used  for urological purposes (15 mg/day), and this may  explain
the  low incidence of side effects observed in this study. Dry
mouth  is  usually benign and decreases with time of use of
medication. In this study there were no reported cases of
treatment  interruption or  discontinuation due to side effects.
However,  more  severe and persistent side-effects can occur,
Table 3  – Improvement in hyperhidrosis after treatment.
Treatment result Score  BMI < 25
n  (%)
25  < BMI < 30
n (%)
BMI > 30
n  (%)
p*
No improvement 0-4 115 (28.0) 39  (32.2) 10  (37.0) 0.444
Partial improvement 5-7 141 (34.3) 35  (28.9) 8 (29.6)
Great improvement 8-10  155 (37.7) 47  (38.9) 9 (33.4)
Total 411 121 27
∗ Chi-squared test comparing “no improvement” with “partial improvement” and “great improvement”.
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especially with higher doses, and may  be a limiting factor for
long-term  use of this medication.24
Conclusion
Overweight and obese patients with PH or AH reported a  sig-
niﬁcant  reduction in sweating and improvement in QOL after
treatment  with oxybutynin; the results are comparable to nor-
mal  weight individuals. The use of oxybutynin in low doses
should  be considered as a simple and efﬁcient therapeutic
alternative to improve the QOL of these patients. Further stud-
ies  are required to analyze the long-term use and safety of this
medication.
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